Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
Authors
Keywords
Surgical amputation, Type 2 diabetes risk, Randomized controlled trials, Metaanalysis, Observational studies, Cardiovascular disease risk, Comparators, Peripheral vascular disease
Journal
PLoS One
Volume 15, Issue 6, Pages e0234065
Publisher
Public Library of Science (PLoS)
Online
2020-06-06
DOI
10.1371/journal.pone.0234065
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists
- (2019) Orly Vardeny et al. JACC-Heart Failure
- AMPUTATION RISK IN PATIENTS TREATED WITH ANTI-DIABETIC DRUGS INCLUDING SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR AND INCRETINS: A COMPARATIVE REAL-WORLD OUTCOME STUDY
- (2019) Sanjoy Paul et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- COMPARATIVE EFFECTIVENESS AND SAFETY OF EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
- (2019) Elisabetta Patorno et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
- (2019) David R. Matthews et al. DIABETOLOGIA
- Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A Meta-analysis Of Randomized Controlled Trials
- (2019) Ilaria Dicembrini et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence
- (2019) Niki Katsiki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- 156-OR: Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
- (2019) ELISABETTA PATORNO et al. DIABETES
- 1539-P: Assessing the Risk of Amputation with Canagliflozin in Middle-Aged Adults and Adults over 65 Years of Age: An Observational Study Using Three Nationwide Databases
- (2019) MICHAEL FRALICK et al. DIABETES
- PDB7 DIABETIC COMPLICATIONS ASSOCIATED WITH SGLT2 AND DPP4 INHIBITORS: A REAL-WORLD APPROACH
- (2019) R. Kashambwa et al. VALUE IN HEALTH
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
- (2019) Carol Pollock et al. Lancet Diabetes & Endocrinology
- Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis
- (2019) E. G. Dorsey-Treviño et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials
- (2019) Atsunori Kashiwagi et al. Diabetes Therapy
- Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
- (2019) Hirohito Sone et al. DIABETES OBESITY & METABOLISM
- Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial
- (2018) Ryuzo Kawamori et al. DIABETES OBESITY & METABOLISM
- Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER
- (2018) Patrick B. Ryan et al. DIABETES OBESITY & METABOLISM
- Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS)
- (2018) Yasuo Terauchi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
- (2018) Paola Fioretto et al. DIABETES OBESITY & METABOLISM
- Risk of Amputations Associated with SGLT2 Inhibitors Compared to DPP-4 Inhibitors: A Propensity-Matched Cohort Study
- (2018) Sruthi Adimadhyam et al. DIABETES OBESITY & METABOLISM
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review
- (2018) Karin Rådholm et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes
- (2018) Ghadeer K. Dawwas et al. DIABETES OBESITY & METABOLISM
- Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials
- (2018) Daisuke Yabe et al. Journal of Diabetes Investigation
- Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
- (2018) Hsien-Yen Chang et al. JAMA Internal Medicine
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
- (2017) Priscilla Hollander et al. Diabetes Therapy
- Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
- (2017) Priscilla Hollander et al. Diabetes Therapy
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug safety assessment in clinical trials: methodological challenges and opportunities
- (2012) Sonal Singh et al. Trials
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started